Literature DB >> 26942067

Density of tumor-infiltrating lymphocytes correlates with extent of brain edema and overall survival time in patients with brain metastases.

Anna S Berghoff1, Elisabeth Fuchs1, Gerda Ricken2, Bernhard Mlecnik3, Gabriela Bindea3, Thomas Spanberger1, Monika Hackl4, Georg Widhalm5, Karin Dieckmann6, Daniela Prayer7, Amelie Bilocq3, Harald Heinzl8, Christoph Zielinski1, Rupert Bartsch1, Peter Birner9, Jerome Galon3, Matthias Preusser1.   

Abstract

The immune microenvironment of the brain differs from that of other organs and the role of tumor-infiltrating lymphocytes (TILs) in brain metastases (BM), one of the most common and devastating complication of cancer, is unclear. We investigated TIL subsets and their prognostic impact in 116 BM specimens using immunohistochemistry for CD3, CD8, CD45RO, FOXP3, PD1 and PD-L1. The Immunoscore was calculated as published previously. Overall, we found TIL infiltration in 115/116 (99.1%) BM specimens. PD-L1 expression was evident in 19/67 (28.4%) BM specimens and showed no correlation with TIL density (p > 0.05). TIL density was not associated with corticosteroid administration (p > 0.05). A significant difference in infiltration density according to TIL subtype was present (p < 0.001; Chi Square); high infiltration was most frequently observed for CD3+ TILs (95/116; 81.9%) and least frequently for PD1+ TILs (18/116; 15.5%; p < 0.001). Highest TIL density was observed in melanoma, followed by renal cell cancer and lung cancer BM (p < 0.001). The density of CD8+ TILs correlated positively with the extent of peritumoral edema seen on pre-operative magnetic resonance imaging (p = 0.031). The density of CD3+ (15 vs. 6 mo; p = 0.015), CD8+ (15 vs. 11 mo; p = 0.030) and CD45RO+ TILs (18 vs. 8 mo; p = 0.006) showed a positive correlation with favorable median OS times. Immunoscore showed significant correlation with survival prognosis (27 vs. 10 mo; p < 0.001). The prognostic impact of Immunoscore was independent from established prognostic parameters at multivariable analysis (HR 0.612, p < 0.001). In conclusion, our data indicate that dense TILs infiltrates are common in BM and correlate with the amount of peritumoral brain edema and survival prognosis, thus identifying the immune system as potential biomarker for cancer patients with CNS affection. Further studies are needed to substantiate our findings.

Entities:  

Keywords:  brain metastases; immunoscore; overall survival; prognosis; tumor infiltrating lymphocytes

Year:  2015        PMID: 26942067      PMCID: PMC4760339          DOI: 10.1080/2162402X.2015.1057388

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN: 2162-4011            Impact factor:   8.110


  29 in total

1.  Effector memory T cells, early metastasis, and survival in colorectal cancer.

Authors:  Franck Pagès; Anne Berger; Matthieu Camus; Fatima Sanchez-Cabo; Anne Costes; Robert Molidor; Bernhard Mlecnik; Amos Kirilovsky; Malin Nilsson; Diane Damotte; Tchao Meatchi; Patrick Bruneval; Paul-Henri Cugnenc; Zlatko Trajanoski; Wolf-Herman Fridman; Jérôme Galon
Journal:  N Engl J Med       Date:  2005-12-22       Impact factor: 91.245

2.  A new prognostic index and comparison to three other indices for patients with brain metastases: an analysis of 1,960 patients in the RTOG database.

Authors:  Paul W Sperduto; Brian Berkey; Laurie E Gaspar; Minesh Mehta; Walter Curran
Journal:  Int J Radiat Oncol Biol Phys       Date:  2007-10-10       Impact factor: 7.038

3.  Improved IL-2 immunotherapy by selective stimulation of IL-2 receptors on lymphocytes and endothelial cells.

Authors:  Carsten Krieg; Sven Létourneau; Giuseppe Pantaleo; Onur Boyman
Journal:  Proc Natl Acad Sci U S A       Date:  2010-06-14       Impact factor: 11.205

Review 4.  Dangers of using "optimal" cutpoints in the evaluation of prognostic factors.

Authors:  D G Altman; B Lausen; W Sauerbrei; M Schumacher
Journal:  J Natl Cancer Inst       Date:  1994-06-01       Impact factor: 13.506

5.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

Authors:  Suzanne L Topalian; F Stephen Hodi; Julie R Brahmer; Scott N Gettinger; David C Smith; David F McDermott; John D Powderly; Richard D Carvajal; Jeffrey A Sosman; Michael B Atkins; Philip D Leming; David R Spigel; Scott J Antonia; Leora Horn; Charles G Drake; Drew M Pardoll; Lieping Chen; William H Sharfman; Robert A Anders; Janis M Taube; Tracee L McMiller; Haiying Xu; Alan J Korman; Maria Jure-Kunkel; Shruti Agrawal; Daniel McDonald; Georgia D Kollia; Ashok Gupta; Jon M Wigginton; Mario Sznol
Journal:  N Engl J Med       Date:  2012-06-02       Impact factor: 91.245

6.  Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction.

Authors:  Bernhard Mlecnik; Marie Tosolini; Amos Kirilovsky; Anne Berger; Gabriela Bindea; Tchao Meatchi; Patrick Bruneval; Zlatko Trajanoski; Wolf-Herman Fridman; Franck Pagès; Jérôme Galon
Journal:  J Clin Oncol       Date:  2011-01-18       Impact factor: 44.544

Review 7.  The continuum of cancer immunosurveillance: prognostic, predictive, and mechanistic signatures.

Authors:  Jérôme Galon; Helen K Angell; Davide Bedognetti; Francesco M Marincola
Journal:  Immunity       Date:  2013-07-25       Impact factor: 31.745

8.  HLA class I antigen processing machinery component expression and intratumoral T-Cell infiltrate as independent prognostic markers in ovarian carcinoma.

Authors:  Liz Y Han; Mavis S Fletcher; Diana L Urbauer; Peter Mueller; Charles N Landen; Aparna A Kamat; Yvonne G Lin; William M Merritt; Whitney A Spannuth; Michael T Deavers; Koen De Geest; David M Gershenson; Susan K Lutgendorf; Soldano Ferrone; Anil K Sood
Journal:  Clin Cancer Res       Date:  2008-06-01       Impact factor: 12.531

9.  What is immune privilege (not)?

Authors:  Ian Galea; Ingo Bechmann; V Hugh Perry
Journal:  Trends Immunol       Date:  2006-11-28       Impact factor: 16.687

Review 10.  Towards the introduction of the 'Immunoscore' in the classification of malignant tumours.

Authors:  Jérôme Galon; Bernhard Mlecnik; Gabriela Bindea; Helen K Angell; Anne Berger; Christine Lagorce; Alessandro Lugli; Inti Zlobec; Arndt Hartmann; Carlo Bifulco; Iris D Nagtegaal; Richard Palmqvist; Giuseppe V Masucci; Gerardo Botti; Fabiana Tatangelo; Paolo Delrio; Michele Maio; Luigi Laghi; Fabio Grizzi; Martin Asslaber; Corrado D'Arrigo; Fernando Vidal-Vanaclocha; Eva Zavadova; Lotfi Chouchane; Pamela S Ohashi; Sara Hafezi-Bakhtiari; Bradly G Wouters; Michael Roehrl; Linh Nguyen; Yutaka Kawakami; Shoichi Hazama; Kiyotaka Okuno; Shuji Ogino; Peter Gibbs; Paul Waring; Noriyuki Sato; Toshihiko Torigoe; Kyogo Itoh; Prabhu S Patel; Shilin N Shukla; Yili Wang; Scott Kopetz; Frank A Sinicrope; Viorel Scripcariu; Paolo A Ascierto; Francesco M Marincola; Bernard A Fox; Franck Pagès
Journal:  J Pathol       Date:  2014-01       Impact factor: 7.996

View more
  101 in total

1.  Tumor infiltrating lymphocytes and PD-L1 expression in brain metastases of small cell lung cancer (SCLC).

Authors:  Anna Sophie Berghoff; Gerda Ricken; Dorothee Wilhelm; Orsolya Rajky; Georg Widhalm; Karin Dieckmann; Peter Birner; Rupert Bartsch; Matthias Preusser
Journal:  J Neurooncol       Date:  2016-07-19       Impact factor: 4.130

2.  Perilesional edema in brain metastasis from non-small cell lung cancer (NSCLC) as predictor of response to radiosurgery (SRS).

Authors:  Paolo Tini; Valerio Nardone; Pierpaolo Pastina; Giuseppe Battaglia; Claudia Vinciguerra; Tommaso Carfagno; Giovanni Rubino; Salvatore Francesco Carbone; Lucio Sebaste; Alfonso Cerase; Antonio Federico; Luigi Pirtoli
Journal:  Neurol Sci       Date:  2017-03-04       Impact factor: 3.307

Review 3.  Are immune checkpoint blockade monoclonal antibodies active against CNS metastases from NSCLC?-current evidence and future perspectives.

Authors:  Grainne M O'Kane; Natasha B Leighl
Journal:  Transl Lung Cancer Res       Date:  2016-12

Review 4.  Systemic Therapy of Lung Cancer CNS Metastases Using Molecularly Targeted Agents and Immune Checkpoint Inhibitors.

Authors:  Grainne M O'Kane; Natasha B Leighl
Journal:  CNS Drugs       Date:  2018-06       Impact factor: 5.749

Review 5.  Assessing Tumor-infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method From the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma In Situ, Metastatic Tumor Deposits and Areas for Further Research.

Authors:  Shona Hendry; Roberto Salgado; Thomas Gevaert; Prudence A Russell; Tom John; Bibhusal Thapa; Michael Christie; Koen van de Vijver; M V Estrada; Paula I Gonzalez-Ericsson; Melinda Sanders; Benjamin Solomon; Cinzia Solinas; Gert G G M Van den Eynden; Yves Allory; Matthias Preusser; Johannes Hainfellner; Giancarlo Pruneri; Andrea Vingiani; Sandra Demaria; Fraser Symmans; Paolo Nuciforo; Laura Comerma; E A Thompson; Sunil Lakhani; Seong-Rim Kim; Stuart Schnitt; Cecile Colpaert; Christos Sotiriou; Stefan J Scherer; Michail Ignatiadis; Sunil Badve; Robert H Pierce; Giuseppe Viale; Nicolas Sirtaine; Frederique Penault-Llorca; Tomohagu Sugie; Susan Fineberg; Soonmyung Paik; Ashok Srinivasan; Andrea Richardson; Yihong Wang; Ewa Chmielik; Jane Brock; Douglas B Johnson; Justin Balko; Stephan Wienert; Veerle Bossuyt; Stefan Michiels; Nils Ternes; Nicole Burchardi; Stephen J Luen; Peter Savas; Frederick Klauschen; Peter H Watson; Brad H Nelson; Carmen Criscitiello; Sandra O'Toole; Denis Larsimont; Roland de Wind; Giuseppe Curigliano; Fabrice André; Magali Lacroix-Triki; Mark van de Vijver; Federico Rojo; Giuseppe Floris; Shahinaz Bedri; Joseph Sparano; David Rimm; Torsten Nielsen; Zuzana Kos; Stephen Hewitt; Baljit Singh; Gelareh Farshid; Sibylle Loibl; Kimberly H Allison; Nadine Tung; Sylvia Adams; Karen Willard-Gallo; Hugo M Horlings; Leena Gandhi; Andre Moreira; Fred Hirsch; Maria V Dieci; Maria Urbanowicz; Iva Brcic; Konstanty Korski; Fabien Gaire; Hartmut Koeppen; Amy Lo; Jennifer Giltnane; Marlon C Rebelatto; Keith E Steele; Jiping Zha; Kenneth Emancipator; Jonathan W Juco; Carsten Denkert; Jorge Reis-Filho; Sherene Loi; Stephen B Fox
Journal:  Adv Anat Pathol       Date:  2017-09       Impact factor: 3.875

Review 6.  A Blazing Landscape: Neuroinflammation Shapes Brain Metastasis.

Authors:  Hila Doron; Tobias Pukrop; Neta Erez
Journal:  Cancer Res       Date:  2019-01-24       Impact factor: 12.701

Review 7.  Salting the Soil: Targeting the Microenvironment of Brain Metastases.

Authors:  Ethan S Srinivasan; Aaron C Tan; Carey K Anders; Ann Marie Pendergast; Dorothy A Sipkins; David M Ashley; Peter E Fecci; Mustafa Khasraw
Journal:  Mol Cancer Ther       Date:  2021-01-05       Impact factor: 6.261

8.  Additional Support for the Introduction of Immune Cell Quantification in Colorectal Cancer Classification.

Authors:  Robert L Ferris; Jérôme Galon
Journal:  J Natl Cancer Inst       Date:  2016-05-12       Impact factor: 13.506

9.  Tumor immune microenvironment in brain metastases from gynecologic malignancies.

Authors:  Corey M Gill; Megan R D'Andrea; Shannon Tomita; Jessa Suhner; Melissa Umphlett; Konstantin Zakashansky; Stephanie V Blank; Nadejda Tsankova; Raj K Shrivastava; Mary Fowkes; Valentin Kolev
Journal:  Cancer Immunol Immunother       Date:  2021-03-13       Impact factor: 6.968

10.  Role of perilesional edema and tumor volume in the prognosis of non-small cell lung cancer (NSCLC) undergoing radiosurgery (SRS) for brain metastases.

Authors:  Valerio Nardone; Sara Nanni; Pierpaolo Pastina; Claudia Vinciguerra; Alfonso Cerase; Pierpaolo Correale; Cesare Guida; Antonio Giordano; Paolo Tini; Alfonso Reginelli; Salvatore Cappabianca; Luigi Pirtoli
Journal:  Strahlenther Onkol       Date:  2019-05-23       Impact factor: 3.621

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.